Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study - Tregouet, DA; Schnabel, R; Alessi, MC (J Thromb Haemost, 2009)